Ask AI
Menin Inhibitors in AML

CME

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors? 

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: September 09, 2025

Expiration: March 08, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Han X, et al. Global, regional, and national burden of acute leukemia and its risk factors from 1990 to 2021 and predictions to 2040: Findings from the global burden of disease study 2021. Biomedical Engineering Online. 2025;24:72.
  2. Issa G, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35:2482.
  3. Krivtsov AV, et al. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823-833.
  4. Swaminatham M, et al. Menin inhibitors in acute myeloid leukemia—What does the future hold? Cancer J. 2022;28:62
  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: acute myeloid leukemia. v.2.2025. nccn.org. Accessed August 26, 2025.
  6. Falini B, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): Is it a distinct entity? Blood. 2011;117:1109.
  7. Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345.
  8. Thorsteinsdottir U, et al. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21:224-234.
  9. Grembecka J, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. 2012;8:277-284.
  10. Krivtsov AV, et al. A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36:660-673.
  11. Uckelmann HJ, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367:586-590.
  12. Issa GC, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukemia. Nature. 2023;615:920.
  13. Revumenib [prescribing information]. Waltham, MA: Syndax Pharmaceuticals, Inc; 2024.
  14. Arellano M, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study. Blood. 2025;[Epub ahead of print].
  15. Zeidner J, et al. Azacitidine, venetoclax, and revumenib for newly diagnosed older adults with acute myeloid leukemia (AML) and NPM1 mutation or KMT2A rearrangement: Updated results from the beat AML consortium. Presented at The European Hematology Association Congress 2025. 4159215;S138.
  16. Zeidner J, et al. Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML. J Clin Oncology. 2025;V43:N23.
  17. Issa GC, et al. Phase I/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in R/R AML. Blood. 2024;144(Supplement 1):216.
  18. Wang E, et al. Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study. Presented at: American Society of Clinical Oncology 2025. Abstract 6506.
  19. Smith C, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Advances. 2022;6:2144.
  20. Erba H, et al. Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-M Or KMT2A-R acute myeloid leukemia (AML): Updated phase 1a/b results from Komet-007. Presented at The European Hematology Association Congress 2025. 4159213:S136.
  21. Fathi A, et al. Ziftomenib combined with venetoclax/azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Interim phase 1a results from KOMET-007. Blood 2024;144(Supplement 1):2880.
  22. Searle E, et al. Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed/refractory acute leukemia patients with KMT2A and NPM1 alterations. Blood 2024;144 (Supplement 1):212.
  23. Wei A, et al. Rp2d determination of bleximenib in combination with ven+aza: Phase 1b study in ND & R/R AML with KMT2A/NPM1 alterations. Presented at The European Hematology Association Congress 2025. 4159214:S137.
  24. Zeidner J, et al. Phase 1 results: First-in-human phase 1/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood 2024;144 (Supplement 1):213.
  25. Hughes J, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18:4872-4875.
  26. Yukawa T, et al. Utility of physicochemical properties for the prediction of toxicological outcomes: Takeda perspective. ACS Med Chem Lett. 2020;V11:I2
  27. Perner F, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 2023;615:913.
  28. Grimwade D, et al. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127:29.
  29. Kleppe M, et al. Tumor heterogeneity confounds and illuminates: assessing the implications. Nat Med. 2014;20:342-4.
  30. Wang E, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol 2024;25:1310.
  31. Aldoss I, et al. Updated Results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R/R) KMT2Ar acute leukemia. Blood 2024;144 (Supplement 1):211.